MA45381A - Formulation de vaccin contre le vih - Google Patents

Formulation de vaccin contre le vih

Info

Publication number
MA45381A
MA45381A MA045381A MA45381A MA45381A MA 45381 A MA45381 A MA 45381A MA 045381 A MA045381 A MA 045381A MA 45381 A MA45381 A MA 45381A MA 45381 A MA45381 A MA 45381A
Authority
MA
Morocco
Prior art keywords
vaccine formulation
hiv vaccine
hiv
formulation
vaccine
Prior art date
Application number
MA045381A
Other languages
English (en)
Inventor
Mark Bruner
Thierry-Thien NGUYEN
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MA45381A publication Critical patent/MA45381A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
MA045381A 2016-06-16 2017-06-15 Formulation de vaccin contre le vih MA45381A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662350919P 2016-06-16 2016-06-16

Publications (1)

Publication Number Publication Date
MA45381A true MA45381A (fr) 2021-04-21

Family

ID=59093548

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045381A MA45381A (fr) 2016-06-16 2017-06-15 Formulation de vaccin contre le vih

Country Status (15)

Country Link
US (3) US10273268B2 (fr)
EP (1) EP3471765B1 (fr)
JP (1) JP6595132B2 (fr)
KR (1) KR102389489B1 (fr)
CN (1) CN109219448B (fr)
AU (2) AU2017286375B2 (fr)
BR (1) BR112018075785A2 (fr)
CA (1) CA3027454A1 (fr)
EA (1) EA201892735A1 (fr)
IL (1) IL263624B (fr)
MA (1) MA45381A (fr)
MX (1) MX2018015361A (fr)
PH (1) PH12018502403A1 (fr)
SG (1) SG11201810549TA (fr)
WO (1) WO2017216288A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368157B (zh) 2015-12-15 2022-04-15 扬森疫苗与预防公司 人类免疫缺陷病毒抗原、载体、组合物、及其使用方法
JP6595132B2 (ja) 2016-06-16 2019-10-23 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｉｖワクチン製剤
WO2018045267A1 (fr) 2016-09-02 2018-03-08 Janssen Vaccines & Prevention B.V. Procédés pour induire une réponse immunitaire contre une infection par le virus de l'immunodéficience humaine chez des sujets subissant un traitement antirétroviral
CA3036959A1 (fr) 2016-09-15 2018-03-22 Janssen Vaccines & Prevention B.V. Mutations de proteine d'enveloppe du vih stabilisant la forme trimere
JP7272965B2 (ja) 2017-06-15 2023-05-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｉｖ抗原をコードするポックスウイルスベクターおよびその使用方法
CN110891601A (zh) 2017-07-19 2020-03-17 扬森疫苗与预防公司 三聚体稳定性hiv包膜蛋白突变
WO2020064621A1 (fr) * 2018-09-25 2020-04-02 Janssen Vaccines & Prevention B.V. Méthode d'induction d'une réponse immunitaire contre le virus de l'immunodéficience humaine par administration co-localisée de composants vaccinaux
BR112022007929A2 (pt) * 2019-11-07 2022-07-12 Janssen Vaccines & Prevention Bv Purificação de proteínas
CN114903922B (zh) * 2021-02-09 2024-04-26 武汉博沃生物科技有限公司 包含腺病毒的医药配制品及其保存方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197825A (en) 1961-09-07 1965-08-03 Leonard W Hammond Core-pulling mechanism for casting dies
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (fr) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Virus recombinant de la vaccine derive du virus modifie ankara
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
KR100408229B1 (ko) * 1996-10-04 2003-12-01 암겐 인코포레이티드 Ｍｐｌ 리간드를 함유하는 제약학적 조성물
US5761893A (en) 1996-10-22 1998-06-09 Lofquist Welding, Inc. Crop saving attachment for the snouts of combines
EP1816205B1 (fr) 1999-05-17 2011-08-10 Crucell Holland B.V. Adénovirus recombinant basé sur le serotype 48 (Ad48)
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
CA2384271A1 (fr) 1999-09-17 2001-03-22 Joseph G. Sodroski Trimeres stabilises solubles de glycoproteines
EE05680B1 (et) 2000-11-23 2013-10-15 Bavarian Nordic A/S Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin
EP1409694A4 (fr) 2001-07-05 2006-02-08 Chiron Corp Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
EP1456230A2 (fr) 2001-12-04 2004-09-15 Bavarian Nordic A/S Vaccin a sous-unite de ns1 de flavivirus
ES2310247T3 (es) 2002-04-25 2009-01-01 Crucell Holland B.V. Vectores adenovirales estables y metodos de propagacion de los mismos.
SI1497438T1 (sl) 2002-04-25 2010-03-31 Crucell Holland Bv Sredstva in postopki za pripravo adenovirusnih vektorjev
WO2004044155A2 (fr) 2002-11-07 2004-05-27 Beth Israel Deaconess Medical Center Mip-1$g(a) et gm-csf adjuvants de la reponse immune
CA2505583C (fr) 2002-12-03 2014-07-15 University Of Massachusetts Vaccins a adn polyvalents contre la glycoproteine du vih-1 primaire et procedes de vaccination
JP2006520746A (ja) * 2002-12-27 2006-09-14 カイロン コーポレイション リン脂質を含む免疫原性組成物
EP2359851A3 (fr) 2003-03-28 2011-08-31 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services MVA exprimant des gènes enveloppe, gag et pol du vih
US20070166784A1 (en) 2003-09-15 2007-07-19 Barnett Susan W Combination approaches for generating immune responses
WO2005052119A2 (fr) 2003-11-19 2005-06-09 Beth Israel Deaconess Medical Center Adjuvants de la reponse immunitaire
WO2006002079A2 (fr) 2004-06-15 2006-01-05 Progenics Pharmaceuticals, Inc. Anticorps de neutralisation du vih-1 elicites par un complexe trimerique de glycoproteines d'enveloppe du vih-1
WO2006020071A2 (fr) 2004-07-16 2006-02-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructions vaccinales et combinaisons de vaccins conçues pour ameliorer l'etendue de la reaction immunitaire a diverses souches et variantes du vih
DK1789438T3 (en) 2004-08-27 2015-07-20 Us Government Recombinant MVA viruses expressing MODIFIED env, gag and pol genes of HIV CLADE A / G, CLADE CLADE B AND C
CA2583843C (fr) 2004-10-13 2010-09-21 Crucell Holland B.V. Vecteurs adenoviraux ameliores et leurs utilisations
US20100221241A1 (en) 2005-07-06 2010-09-02 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
US8119140B2 (en) 2005-08-23 2012-02-21 Los Alamos Security, LLC Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins
WO2007104792A2 (fr) 2006-03-16 2007-09-20 Crucell Holland B.V. Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci
WO2007149491A2 (fr) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Protéines env vih trimériques solubles stabilisées et leurs utilisations
WO2008063331A2 (fr) 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Polypeptides d'enveloppe gp140 modifiés en provenance d'isolats du vih-1, compositions, complexes trimériques et utilisations de ceux-ci
US20080279879A1 (en) 2006-11-17 2008-11-13 New York University INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
DK2137210T3 (en) 2007-03-02 2017-01-30 Glaxosmithkline Biologicals Sa Hitherto unknown method and compositions
TR201802130T4 (tr) 2008-10-10 2018-03-21 Beth Israel Deaconess Medical Ct Inc Biyokimyasal olarak stabilize edilmiş HIV-1 env trimer aşısı.
HUE042397T2 (hu) 2008-11-18 2019-06-28 Beth Israel Deaconess Medical Ct Inc Javított sejtes immunogenitású vírusellenes oltóanyagok
WO2010096561A1 (fr) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines gag du vih/vis de synthèse et leurs utilisations
WO2011082087A2 (fr) 2010-01-04 2011-07-07 Kj Biosciences, Llc Protéines de fusion avec des dps destinées à être utilisées dans des vaccins et des produits de diagnostic
NZ600629A (en) 2010-01-28 2014-12-24 Bavarian Nordic As Vaccinia virus mutants containing the major genomic deletions of mva
EP2611465A4 (fr) 2010-08-31 2014-06-04 Theraclone Sciences Inc Anticorps neutralisants anti-virus de l'immunodéficience humaine (vih)
JP5933565B2 (ja) 2010-10-15 2016-06-15 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換え改変ワクシニアウイルスアンカラインフルエンザワクチン
ES2676196T3 (es) 2010-12-14 2018-07-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vacunas contra filovirus de adenovirus de serotipo 25 y serotipo 35
WO2013036791A2 (fr) 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Vecteurs adénoviraux modifiés et procédés de traitement dans lesquels ils interviennent
EP2568289A3 (fr) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants
WO2013055908A1 (fr) 2011-10-12 2013-04-18 The Scripps Research Institute Mini boucle v3 de gp120 du vih-1 et ses utilisations
US10160808B2 (en) * 2012-02-16 2018-12-25 Santarus, Inc. Anti-VLA1 (CD49A) antibody pharmaceutical compositions
AU2013228096B2 (en) * 2012-03-05 2017-07-13 Intravacc B.V. Methods and compositions for stabilizing dried biological materials
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
EP2896015A4 (fr) 2012-09-13 2016-04-20 Parkland Ct For Clinical Innovation Système et procédé d'interface utilisateur pour tableau de bord clinique
US9683268B2 (en) 2012-09-19 2017-06-20 Beth Israel Deaconess Viruses associated with immunodeficiency and enteropathy and methods using same
WO2014078688A2 (fr) 2012-11-16 2014-05-22 Beth Israel Deaconess Medical Center, Inc. Adénovirus recombinants et leur utilisation
AU2014203886B2 (en) * 2013-01-07 2017-11-02 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
WO2015048770A2 (fr) 2013-09-30 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Traitements par anticorps pour le virus de l'immunodéficience humaine (vih)
US9750801B2 (en) 2014-02-28 2017-09-05 Janssen Vaccines & Prevention B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
WO2016037154A1 (fr) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Protéines de l'enveloppe du vih-1 recombinantes et leur utilisation
PT3197489T (pt) 2014-09-26 2021-04-30 Beth Israel Deaconess Medical Ct Inc Métodos e composições para induzir a imunidade protetora contra a infeção pelo vírus da imunodeficiência humana
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
DK3271729T3 (da) 2015-03-18 2020-12-14 Janssen Vaccines & Prevention Bv Analyser til rekombinante ekspressionssystemer
CN108368157B (zh) 2015-12-15 2022-04-15 扬森疫苗与预防公司 人类免疫缺陷病毒抗原、载体、组合物、及其使用方法
JP6595132B2 (ja) 2016-06-16 2019-10-23 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｉｖワクチン製剤
WO2018045267A1 (fr) 2016-09-02 2018-03-08 Janssen Vaccines & Prevention B.V. Procédés pour induire une réponse immunitaire contre une infection par le virus de l'immunodéficience humaine chez des sujets subissant un traitement antirétroviral
CA3036959A1 (fr) 2016-09-15 2018-03-22 Janssen Vaccines & Prevention B.V. Mutations de proteine d'enveloppe du vih stabilisant la forme trimere

Also Published As

Publication number Publication date
PH12018502403A1 (en) 2019-09-16
EP3471765B1 (fr) 2024-04-24
US10273268B2 (en) 2019-04-30
BR112018075785A2 (pt) 2019-04-02
SG11201810549TA (en) 2018-12-28
KR102389489B1 (ko) 2022-04-22
JP6595132B2 (ja) 2019-10-23
WO2017216288A1 (fr) 2017-12-21
US11603389B2 (en) 2023-03-14
US10934328B2 (en) 2021-03-02
CA3027454A1 (fr) 2017-12-21
IL263624A (en) 2019-01-31
CN109219448B (zh) 2022-09-20
MX2018015361A (es) 2019-03-11
AU2017286375A1 (en) 2018-12-06
US20210179670A1 (en) 2021-06-17
US20170362280A1 (en) 2017-12-21
EP3471765A1 (fr) 2019-04-24
AU2017286375B2 (en) 2019-04-18
KR20190020020A (ko) 2019-02-27
US20190202870A1 (en) 2019-07-04
CN109219448A (zh) 2019-01-15
JP2019523773A (ja) 2019-08-29
AU2019205994A1 (en) 2019-08-01
IL263624B (en) 2022-04-01
EA201892735A1 (ru) 2019-05-31

Similar Documents

Publication Publication Date Title
MA46766A (fr) Vaccin antigrippal
ZA201801035B (en) Vaccine compositions
MA45381A (fr) Formulation de vaccin contre le vih
DK3393510T3 (da) Zikavirusvaccine
MA43762A (fr) Vaccin contre le rsv
MA50541A (fr) Formulations pharmaceutiques
HK1254343A1 (zh) 藥物製劑
ZA201903101B (en) Pharmaceutical formulations
DK3634377T3 (da) Farmaceutisk formulering
BR112017028011A2 (pt) vacinas de gripe correspondentes antigenicamente
IL262745A (en) Improved preparations containing drugs
DK3129007T3 (da) Vaccinesammensætninger
PT3426294T (pt) Formulação farmacêutica compreendendo anticorpo, ciclodextrina e metionina
IL266537A (en) pharmaceutical preparation
HK1245653A1 (zh) 藥物製劑
IL254794A0 (en) Pharmaceutical formulations
IL253177B (en) Pharmacy preparation
ZA201807851B (en) Pharmaceutical formulation
DK3601277T3 (da) Farmaceutisk formulering
GB201506755D0 (en) Novel pharmaceutical formulation
BR112016027580A2 (pt) Formulação de ceritinib
MA43166A (fr) Formulation de fviii
ITUA20163470A1 (it) Formulazione antiappannante
GB201511246D0 (en) Pharmaceutical formulation
GB201717288D0 (en) Hiv vaccine